AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Esperion Therapeutics Shares Soar 4.65% on Revenue Growth
Generated by AI AgentAinvest Movers Radar
Friday, Apr 4, 2025 5:07 am ET1min read
Esperion Therapeutics, Inc. (ESPR) shares surged 4.65% in pre-market trading on April 4, 2025, reflecting a positive sentiment among investors.
Esperion Therapeutics, Inc. (ESPR) has a Zacks Rank #3 (Hold), indicating a neutral outlook for the stock in the near term. Analysts expect the company to report earnings of -$0.18 per share in its upcoming earnings release on May 6, 2025.
The company's financial performance shows strong revenue growth, with a year-over-year increase of 114.30%. This robust growth is supported by a gross margin of 62.91%, highlighting Esperion's operational efficiency. The stock's price-to-sales ratio stands at 0.83x, suggesting that the market values the company's sales at a reasonable level.
Esperion Therapeutics has a significant short interest, with 28.90 million shares shorted, representing 14.87% of the float. This high short interest could indicate bearish sentiment among some investors, but it also presents an opportunity for a short squeeze if the stock price continues to rise.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
Two Harbors (TWO) Surges 1.59% to Monthly High Amid Anticipation of $1.3B UWM Acquisition
Dec.19 2025
Trane Technologies Surges 1.46% on Q3 Earnings, Analysts Target $550
Dec.19 2025
Rivian (RIVN) Surges 27.34% on Analyst Upgrades, Q3 Revenue Growth Drives Rebound
Dec.19 2025
Tata Chemicals Share Price Soars 119.32% on Novabay Acquisition Drive
Dec.19 2025
X3 Holdings (XTKG) Rallies 36.76% Intraday, 22.50% in Three Sessions on Technical Rebound and Speculative Buying
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet